Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incannex Healthcare Inc. - Common Stock (NQ: IXHL ) 2.770 +0.350 (+14.46%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Incannex Healthcare Inc. - Common Stock Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) October 02, 2024 Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on... Via Newsfile Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives September 09, 2024 New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a... Via Newsfile Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) May 01, 2024 Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to... Via Newsfile 5 Biotech stocks tapping into unmet mental health treatment needs December 20, 2023 Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. Via MarketBeat Incannex preparing psilocybin therapy FDA IND application August 24, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley tells Proactive the company is preparing an application to gain key regulatory approval to begin clinical trials in... Via TheNewswire.com Exposures Product Safety Incannex full steam ahead towards sleep apnoea trial August 23, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin... Via TheNewswire.com Topics Cannabis Exposures Cannabis Product Safety Incannex thrilled with positive pre-IND meeting for arthritis treatment July 27, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting... Via TheNewswire.com Exposures Product Safety Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial July 18, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical... Via TheNewswire.com Incannex CEO talks plans to redomicile to US July 11, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun the process of shifting all outstanding shares to the Nasdaq after making the decision to redomicile... Via TheNewswire.com Incannex appoints principal investigators for pivotal IHL-42X trial June 19, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,... Via TheNewswire.com Exposures Product Safety Incannex welcomes world-leading psychedelics experts to advisory board June 01, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group... Via TheNewswire.com Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A May 03, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics... Via TheNewswire.com Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use March 03, 2023 Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce... Via TheNewswire.com Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial February 28, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients... Via TheNewswire.com Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea: Incannex Healthcare Limited (NASDAQ: IXHL) May 24, 2022 Via Get News Exposures Product Safety Advancements for Anxiety, Sleep Apnea, Brain Injury, Lung Inflammation, Rheumatoid Arthritis & Inflammatory Bowel Disease: Incannex Healthcare Limited (NASDAQ: IXHL) May 05, 2022 Via Get News Topics Intellectual Property Exposures Intellectual Property Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
